FDA Grants IDE Approval for OCS Heart ENHANCE Trial
Andover, Massachusetts | February 9, 2026 — TransMedics Group has received full and unconditional Investigational Device Exemption (IDE) approval...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Device Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
Andover, Massachusetts | February 9, 2026 — TransMedics Group has received full and unconditional Investigational Device Exemption (IDE) approval...
DULUTH, Ga., Oct. 7, 2025 — Bridge to Life Ltd. has received FDA 510(k) clearance for its multi-sourced Belzer...
